Jasper Therapeutics Q4 EPS $(0.32) Beats $(0.64) Estimate

Jasper Therapeutics (NASDAQ: JSPR) reported Q4 earnings with a loss of $(0.32) per share, surpassing the analyst estimate of $(0.64) by 50.31%. This marks an 80.25% improvement compared to losses of $(1.62) per share in the same quarter last year.